Parkinson’s Disease Drugs Market Size, Share, Trends and Industry Analysis By Drug Class (Decarboxylase Inhibitors, Dopamine Agonists, Monoamine Oxidase Type B (MAO-B) Inhibitor, Catechol-O-Methyltransferase (COMT) Inhibitors), Route of Administration (Oral, Injection, Transdermal), Distribution Channels (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy) & Regional Forecast, 2019 - 2032

Table of Content:

1. Introduction

1.1. Research Scope

1.2. Market Segmentation

1.3. Research Methodology

1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

3.1. Market Drivers

3.2. Market Restraints

3.3. Market Opportunities 

3.4  Market Trends

4. Key Insights

4.1 Prevalence of Parkinson's Disease - For Key Countries, 2018

4.2 Regulatory Scenario - For Key Countries

4.3 Patent Snapshot

4.3 New Product Launch

4.4 Pipeline Analysis

4.5 Key Industry Developments -Mergers, Acquisitions and Partnerships

5. Global Parkinson's Disease Drugs Market Analysis, Insights and Forecast, 2014-2025 

5.1. Key Findings / Summary

5.2. Market Analysis, Insights and Forecast – By Drug Class

5.2.1 Decarboxylase Inhibitors

5.2.2 DopamineAgonists

5.2.3 Monoamine Oxidase Type B (MAO-B) Inhibitors

5.2.4 Catechol-O-Methyltransferase (COMT) Inhibitors

5.2.5 Others

5.3. Market Analysis, Insights and Forecast – By Route of Administration

5.3.1 Oral

5.3.2 Injection

5.3.3 Transdermal

5.4. Market Analysis, Insights and Forecast – By Distribution Channel

5.4.1 Hospital Pharmacy

5.4.2 Retail Pharmacy

5.4.3 Online Stores

5.5. Market Analysis, Insights and Forecast – By Region

5.5.1 North America

5.5.2 Europe

5.5.3 Asia Pacific 

5.5.4 Latin America

5.5.5 Middle East & Africa

6. North America Parkinson's Disease Drugs Market Analysis, Insights and Forecast, 2014-2025

6.1. Key Findings / Summary

6.2. Market Analysis – By Drug Class

6.2.1 Decarboxylase Inhibitors

6.2.2 Dopamine Agonists

6.2.3 Monoamine Oxidase Type B (MAO-B) Inhibitors

6.2.4 Catechol-O-Methyltransferase (COMT) Inhibitors

6.2.5 Others

6.3. Market Analysis – By Route of Administration

6.3.1 Oral

6.3.2 Injection

6.3.3 Transdermal

6.4. Market Analysis – By Distribution Channel

6.4.1 Hospital Pharmacy

6.4.2 Retail Pharmacy

6.4.3 Online Stores

6.5. Market Analysis – By Country

6.5.1 U.S.

6.5.2 Canada

7. Europe Parkinson's Disease Drugs Market Analysis, Insights and Forecast, 2014-2025 

7.1. Key Findings / Summary

7.2. Market Analysis – By Drug Class

7.2.1 Decarboxylase Inhibitors

7.2.2 Dopamine Agonists

7.2.3 Monoamine Oxidase Type B (MAO-B) Inhibitors

7.2.4 Catechol-O-Methyltransferase (COMT) Inhibitors

7.2.4 Others

7.3. Market Analysis – By Route of Administration

7.3.1 Oral

7.3.2 Injection

7.3.3 Transdermal

7.4. Market Analysis – By Distribution Channel

7.4.1 Hospitals

7.4.2 Retail Pharmacy

7.4.3 Online Stores

7.5. Market Analysis – By Countries/ Sub regions

7.5.1 U.K.

7.5.2 Germany

7.5.3 France

7.5.4 Italy

7.5.5 Spain

7.5.6 Scandinavia 

7.5.7 Rest of Europe

8. Asia Pacific Parkinson's Disease Drugs Market Analysis, Insights and Forecast,2014-2025 

8.1. Key Findings / Summary

8.2. Market Analysis – By Drug Class

8.2.1 Decarboxylase Inhibitors

8.2.2 Dopamine Agonists

8.2.3 Monoamine Oxidase Type B (MAO-B) Inhibitors

8.2.4 Catechol-O-Methyltransferase (COMT) Inhibitors

8.2.5 Others

8.3. Market Analysis – By Route of Administration

8.3.1 Oral

8.3.2 Injection

8.3.3 Transdermal

8.4. Market Analysis – By Distribution Channel

8.4.1 Hospitals

8.4.2 Retail Pharmacy

8.4.3 Online Stores

8.5. Market Analysis – By Countries/ Sub regions

8.5.1 Japan

8.5.2 China

8.5.3 India

8.5.4 Australia

8.5.5 Southeast Asia 

8.5.6 Rest of Asia Pacific

9. Latin America Parkinson's Disease Drugs Market Analysis, Insights and Forecast,2014-2025 

9.1. Key Findings / Summary

9.2. Market Analysis – By Drug Class

9.2.1 Decarboxylase Inhibitors

9.2.2 Dopamine Agonists

9.2.3 Monoamine Oxidase Type B (MAO-B) Inhibitors

9.2.4 Catechol-O-Methyltransferase (COMT) Inhibitors

9.2.5 Others

9.3. Market Analysis – By Route of Administration

9.3.1 Oral

9.3.2 Injection

9.3.3 Transdermal

9.4. Market Analysis – By Distribution Channel

9.4.1 Hospitals

9.4.2 Retail Pharmacy

9.4.3 Online Stores

9.5. Market Analysis – By Countries/ Sub regions

9.5.1 Brazil

9.5.2 Mexico

9.6.3 Rest of Latin America

10. Middle East &Africa Parkinson's Disease Drugs Market Analysis, Insights and Forecast,2014-2025 

10.1. Key Findings / Summary

10.2. Market Analysis – By Drug Class

10.2.1 Decarboxylase Inhibitors

10.2.2 Dopamine Agonists

10.2.3 Monoamine Oxidase Type B (MAO-B) Inhibitors

10.2.4 Catechol-O-Methyltransferase (COMT) Inhibitors

10.2.5 Others

10.3. Market Analysis – By Route of Administration

10.3.1 Oral

10.3.2 Injection

10.3.3 Transdermal

10.4. Market Analysis – By Distribution Channel

10.4.1 Hospitals

10.4.2 Retail Pharmacy

10.4.3 Online Stores

10.5. Market Analysis – By Countries/ Sub regions

10.5.1 South Africa

10.5.2 GCC

10.5.3 Rest of Middle East & Africa

11. Competitive Analysis 

11.1. Key Industry Developments

11.2. Global Market Share Analysis (2018)

11.3. Competition Dashboard

11.4. Comparative Analysis –Major Players

11.5. Company Profiles (Overview,Drug Classes & services, SWOT analysis, Recent developments, strategies,financials (based on availability))

11.5.1 UCB S.A

11.5.2 Pfizer,Inc.

11.5.3 F.Hoffmann-La Roche Ltd

11.5.4 Merck& Co., Inc.

11.5.5 Novartis AG

11.5.6 OrionPharma

11.5.7 TevaPharmaceutical Industries Ltd.

11.5.8 Vertical Pharmaceuticals, LLC

11.5.9 ACADIAPharmaceuticals Inc.

11.5.10 ImpaxLaboratories, Inc.

11.5.11 H.Lundbeck A/S

11.5.12 OtherProminent Players

12. Strategic Recommendations